Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-1162 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax of ABBV-1162
Beta of ABBV-1162
t1/2 of ABBV-1162
AUCt of ABBV-1162
AUCinf of ABBV-1162
| Arm | Type | Description |
|---|---|---|
| ABBV-1162 | EXPERIMENTAL | Participants will receive a single oral dose of ABBV-1162. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive a single oral dose of placebo. |
| Name | Type | Description |
|---|---|---|
| ABBV-1162 | DRUG | Oral |
| Placebo | DRUG | Oral |
Inclusion Criteria: * Healthy individuals in general good health. * Blood pressure and heart rate measurements within specified ranges: systolic blood pressure \< 140 mmHg, diastolic blood pressure \< 90 mmHg, heart rate \<= 100 bpm and \>= 55 bpm, absence of orthostatic hypotension.
ABBV-1162 is an investigational small molecule drug developed by AbbVie Inc. (ticker ABBV). It is being studied in healthy adult volunteers rather than in patients with a specific disease. The program is in Phase 1 clinical development, and the compound has not been approved by the FDA.
ABBV-1162 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating the compound. No partner or co-development arrangement for ABBV-1162 is disclosed.
ABBV-1162 is in Phase 1 clinical development. One Phase 1 trial has been registered and is not yet recruiting, with no completed trials reported. As an investigational agent, ABBV-1162 has not been approved by the FDA for any use.
ABBV-1162 is being evaluated in a single registered Phase 1 trial, NCT07832708, titled a study to assess adverse events and how oral ABBV-1162 moves through the body of healthy adults. The trial is not yet recruiting, is placebo controlled and double blind, and plans to enroll 40 participants.
The ABBV-1162 Phase 1 trial, NCT07832708, is a randomized, double-blind, placebo-controlled study in healthy adult volunteers. It plans to enroll 40 participants of all sexes, aged 18 years and older. The study assesses adverse events and how oral ABBV-1162 moves through the body.